---
title: "Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Special populations"
description: "Formulary evidence on Adrabetadex (Lembaz, VTS-270) in Infantile-onset Niemann-Pick disease type C: Special populations. Topics: Pregnancy, Lactation, Females and males of reproductive potential: fertility in rats, Pediatric use: established and not established populations, and 4 further topics. 8 evidence topics quoted from 1 source."
canonical: "https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/product-information-and-disease-description/special-populations"
published: "2026-11-19T12:08:36-05:00"
modified: "2026-11-19T12:08:36-05:00"
---

# Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Special populations

<a id="heading-2.1.2.8"></a>

## 2.1.2.8 Special Populations

<a id="topic-2.1.2.8-1"></a>

### Pregnancy

> “There are no available data on the use of LEMBAZ in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriage, or other adverse maternal or fetal outcomes.”
> “In animal reproduction studies, intravenous administration of adrabetadex to pregnant rats or rabbits during organogenesis at dose exposures that are 2 and 4 times greater than the maximum recommended human dose (MRHD) based on body surface area resulted in no adverse developmental effects (see Data).”
> “The background risk of major birth defects and miscarriage for females with NPC with neurological manifestations is unknown.”
> “In a pre-postnatal development study conducted in pregnant rats administered intravenous adrabetadex once daily from Gestation Day (GD) 16 through lactation at doses up to 400 mg/kg/day, there was no maternal toxicity; however, pup survival was decreased at 400 mg/kg/day (2 times the MRHD based on body surface area).”

Source: [Lembaz prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220996s000lbl.pdf)

<a id="topic-2.1.2.8-2"></a>

### Lactation

> “There are no data on the presence of adrabetadex in either human or animal milk, the effects on the breastfed infant, or the effects on milk production.”
> “The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for LEMBAZ and any potential adverse effects on the breastfed infant from LEMBAZ or from the underlying maternal condition.”

Source: [Lembaz prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220996s000lbl.pdf)

<a id="topic-2.1.2.8-3"></a>

### Females and males of reproductive potential: fertility in rats

> “In a fertility and early embryonic development study, intravenous administration of adrabetadex to rats once daily from 14 days prior to mating for females and 60 days prior to mating for males, and continuing through GD 8 at doses up to 400 mg/kg/day (2 times the MRHD based on body surface area) did not adversely affect fertility.”

Source: [Lembaz prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220996s000lbl.pdf)

<a id="topic-2.1.2.8-4"></a>

### Pediatric use: established and not established populations

> “The safety and effectiveness of LEMBAZ have been established to reduce the risk of mortality in pediatric patients, who weigh 7 kg or greater, with NPC with neurological manifestations that started at less than 6 years of age.”
> “Use of LEMBAZ for this indication is supported by evidence from integrated analyses of 1 randomized, controlled trial, 2 open-label, single-arm clinical trials, and an expanded access program compared to data from an untreated, contemporaneous, external cohort”
> “The safety and effectiveness of LEMBAZ have not been established to reduce the risk of mortality in pediatric patients with NPC who weigh less than 7 kg or in pediatric patients who developed neurological manifestations starting at 6 years of age and older.”

Source: [Lembaz prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220996s000lbl.pdf)

<a id="topic-2.1.2.8-5"></a>

### Neurological onset at 6 years of age or older

> “The safety and effectiveness of LEMBAZ for the treatment of NPC in patients with neurological manifestations that started at 6 years of age or older has not been established”

Source: [Lembaz prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220996s000lbl.pdf)

<a id="topic-2.1.2.8-6"></a>

### Juvenile animal toxicity: hearing loss in cats and kidney findings in rats

> “In a cat model of NPC, juvenile cats were administered adrabetadex intrathecally at doses of 30, 60, or 120 mg every 14 days, beginning at 3 weeks of age (equivalent to a 6-month-old human infant) and continuing through approximately 24 weeks of age.”
> “Progressive hearing loss was observed in all treatment groups beginning at 8 weeks of age and increasing in a dose-dependent manner with repeated dosing.”
> “Hearing loss was irreversible following treatment cessation, with no improvement in hearing threshold observed up to 12 weeks after the last dose”
> “Dose-related increases in kidney weights that correlated with slight to moderate diffuse microvacuolation of the cortical tubules were observed at 200 mg/kg/day or more.”
> “Hearing was not assessed in this study.”

Source: [Lembaz prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220996s000lbl.pdf)

<a id="topic-2.1.2.8-7"></a>

### Geriatric use

> “Clinical studies of LEMBAZ did not include patients 65 years of age and older to determine if they respond differently from younger adult patients.”

Source: [Lembaz prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220996s000lbl.pdf)

<a id="topic-2.1.2.8-8"></a>

### Renal and hepatic impairment

> “Patients with Renal or Hepatic Impairment: No clinical studies have been conducted to evaluate the pharmacokinetics of adrabetadex in patients with renal or hepatic impairment.”
> “Systemic exposure of adrabetadex is expected to be higher in patients with renal impairment, which is not considered clinically significant.”

Source: [Lembaz prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220996s000lbl.pdf)

## Related pages
- [Adrabetadex (Lembaz): Infantile-onset Niemann-Pick disease type C](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c.md)
- [Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Terms and abbreviations](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/terms-and-abbreviations.md)
- [Adrabetadex (Lembaz): Infantile-onset Niemann-Pick disease type C](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/executive-summary) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/executive-summary.md)
- [Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Product information and disease description](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/product-information-and-disease-description.md)
- [Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Clinical evidence](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/clinical-evidence.md)
- [Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Economic information and modeling report](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/economics) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/economics.md)
- [Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: References](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/references) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/references.md)
